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Introduction 
 
The grant proposal included in this document aims to satisfy the written thesis defense 
requirement for the Masters’ Program in Clinical and Translational Investigation. This grant 
aims to bring Nephrology expertise to the practice of selecting candidates for cisplatin 
chemotherapy in order to develop novel strategies with the goal of reducing nephrotoxicity. Our 
hope is that if successful, this would reduce the burden of kidney disease (acute kidney injury 
and chronic kidney disease) amongst patients receiving cisplatin chemotherapy. An oral thesis 
defense titled “Incidence, Trends and Predictors of Cisplatin Nephrotoxicity” was presented 
using the same database on April 20, 2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Project Summary/Abstract  
 
Cisplatin is a chemotherapy drug that will be used to treat approximately 850,000 new cancer 
patients in 2015. Despite decades of its use, toxicity to the kidney remains a problem in 25-30% 
of the patients. Given the high frequency of kidney toxicity, we see as Nephrologists, a need to 
readdress methods for evaluating candidacy for cisplatin use in Oncology. Through this project, 
we may change the paradigm of selecting candidates and evaluating risk of cisplatin 
chemotherapy, which is an essential step prior to offering this drug as an option to patients. We 
propose to challenge the current method used for estimating kidney function, which is using 
serum creatinine or estimated creatinine clearance by the Cockcroft-Gault equation. Our first aim 
is to compare the estimated glomerular filtration rate (eGFR) equation by the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) for determining eligibility to receive cisplatin, 
since it is the most accurate equation available for estimating kidney function at the present time. 
Our second aim is to derive a risk prediction model using readily available clinical and 
laboratory variables that would enable clinicians to instantly compute the risk of kidney toxicity 
during the office visit and arrive at a graded score. This score could then be presented to patients 
as a low-, medium- or high-risk measure to further inform their decision-making regarding the 
treatment and to jointly (with their physicians) make an informed choice in the context of other 
options available. We propose to achieve the above aims by analyzing a large group of over 6000 
patients that we have assembled using the Research Patient Data Repository (RPDR) and 
Oncology Data Retrieval System (OncDRS), which are large data repositories of patients treated 
at Partners affiliated hospitals and Dana Farber Cancer Institute, respectively. Detailed 
information collected from these patients who have been treated with cisplatin over the past 15 
years includes demographics, chemotherapy, other medications, medical history and laboratory 
values. By performing sophisticated statistical analysis on these data, we will be able to 
understand the strength of these associations and thus identify major risk factors causing kidney 
toxicity. The model will be developed from the larger of the two group of patients treated at one 
hospital (derivation cohort) and testing our findings on the second group (validation cohort). We 
expect the results from this study to influence clinical practice and have lasting, positive short- 
and long-term impact on the overall health of patients receiving this drug; as well as identifying 
and redirecting patients with heightened risk of toxicity. If successful, ours will be the largest 
study on this topic and offer a novel method to address an old problem. 
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Specific Aims  
 
Cisplatin is an alkylating anti-neoplastic agent that will be used as a first or second line treatment 
for an estimated 850,000 new cancers in 2015 in the United States. It was first introduced into 
clinical practice in 1978 and since then has led to greater than 90% cure of testicular cancer and 
helped save lives of millions of patients with 
bladder, cervical, ovarian, lung, gastric, breast, 
head and neck cancers, malignant mesothelioma 
and some less-common tumors. Despite a rapid 
rate of introduction of novel chemotherapeutics in 
oncology, this drug remains the backbone of 
several chemotherapy regimens now five decades 
since its discovery. Two essential issues regarding 
its use that continue to be debated today are: a) 
methods of determining candidacy for cisplatin 
use and b) strategies to mitigate the high incidence 
of nephrotoxicity observed. Given that the kidney 
clears majority of this drug (>90%), addressing 
both these issues requires an accurate estimation 
of renal function. Currently, patients are evaluated 
for cisplatin candidacy based on type of cancer, 
functional status and renal function. There is 
considerable heterogeneity across various 
oncology groups, institutions and countries with regards to the method used to determine renal 
function including serum creatinine (sCr), estimated creatinine clearance (eCrCl) by Cockcroft-
Gault formula, and estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal 
Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. 
Measured creatinine clearance or glomerular filtration rate is preferable but is not employed 
routinely. CKD-EPI, despite using the same variables as the MDRD equation, reclassifies 
approximately 24.4% into a higher eGFR category and 0.6% into a lower eGFR category. For 
reasons displayed in table 1, it is the most widely used equation for eGFR amongst nephrologists. 
Its benefit of increased accuracy at GFR≥60ml/min/1.73m2 is an added advantage since the 
majority of patients receiving cisplatin would fall into that category. However, this method has not 
penetrated as deeply into the oncology practice where accurate estimation of renal function is 
essential to identify candidates best suited to receive drugs with a narrow therapeutic index. During 
the last year, we have assembled a database of over 6000 consecutive patients who received 
cisplatin at the Brigham and Women’s Hospital (BWH), Massachusetts General Hospital (MGH) 
and Dana-Farber Cancer Institute (DFCI) between 2005 and 2015. This database includes 
demographics, laboratory values, medical history, medication history and chemotherapy 
administered. Using these data, we propose the following aims: 
Aim 1: To compare mortality and event-rates of cisplatin nephrotoxicity when eligibility for 
cisplatin use is determined by different methods to estimate pre-treatment kidney function. 
We hypothesize that an eGFR-based candidate selection using CKD-EPI will be superior 
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included ✖ ✔ ✔ ✔ 
IDMS* standardized ✔ ✖ ✔ ✔ 
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Optimized for women ✖ ✖ ✔ ✔ 
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*IDMS: Isotope dilution mass spectrometry 
introduced in 2005 across the country 
compared with eCrCl (by Cockcroft-Gault) and sCr at predicting nephrotoxicity and mortality 
amongst those receiving cisplatin. Patients will be divided into categories based on sCr (!1.5mg/dl 
and >1.5mg/dl) eCrCl (≥60 ml/min or <60ml/min) and eGFR (≥60ml/min/1.73 m2 or 
<60ml/min/1.73 m2).  
Aim 2: To develop and validate a clinically useful predictive model for cisplatin 
nephrotoxicity. We hypothesize that a model using readily available clinical and laboratory 
variables (including best kidney function measure from Aim 1) will be able to identify a large 
majority of patients at risk for nephrotoxicity amongst candidates for cisplatin chemotherapy and 
thus improve upon current standard using a single cutoff.  To this end, we will: 1) Derive a 
predictive model using data from patients treated at DFCI and BWH (deelopment cohort). We will 
then validate this model in a separate set of patients treated at MGH (validation cohort) using AUC 
analysis.  
Collectively, these studies will help provide foundation for a potential paradigm shift in the 
determination of cisplatin candidacy, and help tailor therapy by providing individualized risk 
estimates to patients in the office. 
 
 
 
 
 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Research Strategy 
 
SIGNIFICANCE 
Overall cancer survival has improved to 67%1 for all cancers and increasing emphasis is being 
placed on treatment with a tolerable toxicity profile while maintaining tumor eradication 
properties.2 For instance, since its introduction in 1978, cisplatin has led to a dramatic survival 
advantage of patients with testicular, bladder, cervical, ovarian, lung, gastric, breast, head and 
neck cancers, malignant mesothelioma and some less-common tumors.1,3 Taking testicular 
cancer as the example, introduction of cisplatin has led to patient survival of over 95%3 and has 
added decades to patients’ lives.2 This success, however, has led to patients living longer often 
with effects of long-term toxicity and premature death. There is recent evidence that long-term 
circulating platinum levels are detectable in patients up to 20 years after treatment with cisplatin 
combination chemotherapy.4 Renal function before and after cisplatin exposure is found to be a 
major determinant of long term circulating platinum which in turn is associated with 
hypercholesterolemia, hypertension, parasthesias and hypogonadism.5 Therefore, there might be 
a link between short and long term nephrotoxicity and premature cardiovascular mortality. In 
addition, not only are acute kidney injury (AKI) and chronic kidney disease (CKD) independent 
risk factors for morbidity and mortality in the general population but a small study has recently 
found this to be the case in head and neck cancer patients receiving cisplatin.6 One of the 
strategies of utmost importance to prevent late effects and premature mortality might be to 
attempt to decrease this nephrotoxicity in the short-term, by early recognition and prevention, 
which still continues to be observed in one-third of patients.7-9 How might we reduce the 
nephrotoxicity? Our proposed strategy is to identify an improved method for evaluating 
candidacy for cisplatin use.  
 
Comparison of measures of renal function: 
Cisplatin is a known proximal 
tubular toxin that causes a dose-
dependent drop in glomerular 
filtration rate (GFR).8 Equations 
for estimating GFR have evolved 
since cisplatin was first employed 
in clinical practice and its drug 
dosing was determined, with most 
of the pharmacokinetic studies 
using the Cockcroft-Gault (CG) 
equation (see figure 1). It should 
be noted that the CG equation was 
developed from 249 white men 
with a mean estimated creatinine 
clearance (eCrCl) of 73 ml/min. 
In 1999, the Modification of Diet 
in Renal Disease (MDRD) study 
equation was derived from 1,628 
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men and women of black and white origin. The MDRD equation has been shown to be more 
accurate than CG.10 Later in 2007, the National Kidney Disease Education Program (NKDEP) 
introduced the isotope dilution mass spectrometry (IDMS) reference standard to standardize 
creatinine assays across the country.11 These standardized creatinine assays have improved the 
reliability, reproducibility and accuracy of measurement and have been adopted nationwide.11 
The MDRD equation12 and the later developed higher accuracy Chronic Kidney Disease 
Epidemiology (CKD-EPI) equation was calibrated to include standardized creatinine assays, 
which could not be done for the CG equation due to unavailability of study samples from the 
original cohort. The CKD-EPI equation was developed using 12,150 subjects from diverse 
populations (8,254 for development and 3896 for validation).13 One reason for improvement of 
the CKD-EPI equation over the MDRD was the inclusion of patients with and without chronic 
kidney disease (CKD) as opposed to the MDRD, which was developed using only CKD patients. 
This enabled a more accurate estimate of GFR over a wider range of values with better 
understanding of the complex relationship between creatinine and age, sex and race.14 Thus, the 
CG equation, which continues to be employed in most oncology clinical trials for determining 
patient eligibility, is less accurate than the newer eGFR equations. Moreover, CG was not 
originally designed to be adjusted for body surface area; this lack of BSA adjustment could 
particularly be of concern in cancer patients owing to their low muscle mass.10 Furthermore, the 
CKD-EPI equation offers increased precision over the MDRD for measuring glomerular 
filtration rate (GFR) "60 ml/min/1.73 m2.15 Since the majority of the patients receiving cisplatin 
would presumably fall into this category (i.e. eGFR "60 ml/min/1.73 m2), the CKD-EPI would 
seem to be the preferred choice of all the equations available.16 However, as a result of its 
relatively recent adoption in the nephrology literature and clinical practice, with apparent little 
penetration in non-nephrology specialties, there is scant evidence regarding its potential 
benefit.14,17 Two groups have recently compared eCrCl and CKD-EPI in small studies with 
conflicting results. Tsao et al looked at 116 patients with urothelial cancer in a retrospective 
study and classified eligible vs ineligible patients using CG (with eCrCl <60 ml/min deemed 
ineligible) and CKD-EPI equations (with eGFR<60ml/min/1.73 m2 deemed ineligible). They 
found that using CKD-EPI led to a relative 17% larger pool of eligible patients compared with 
CG, with an 87% concordance rate between the two equations.18 A second study by Pal et al 
retrospectively evaluated 126 patients with bladder cancer and compared eligibility using CG, 
MDRD and CKD-EPI and found that the latter classified the least number of patients eligible for 
cisplatin.19 However, neither of the studies included data on nephrotoxicity rates with the 
reclassification. Hence, there is need for better understanding of the impact of CKD-EPI for GFR 
estimation in a much larger number of patients not restricted to specific cancer types, age, race or 
kidney function.  
 
The need for predictive modeling 
In addition to determining the best method for estimating renal function, it would also be 
clinically useful to develop a predictive model that estimates risk of cisplatin nephrotoxicity 
similar to the Framingham risk score’s prediction of cardiovascular disease.20 This scoring 
system would enable identification of those individuals at high risk for nephrotoxicity and lead to 
consideration of appropriate steps for prevention, including use of alternative therapies. To date, 
there is limited understanding of risk factors for cisplatin nephrotoxicity. deJongh et al published 
a multivariable analysis of various types of toxicities in 400 patients who participated in Phase 
I/II clinical trials of two different cisplatin based regimens.21 They reported a 7% rate of 
nephrotoxicity (defined as "25% decline in creatinine clearance) that was associated with older 
age, female, smoking, hypoalbuminemia and paclitaxel co-administration on multivariable 
analysis. This study is not generalizable given the highly selected population of patients. 
Moreover, the rate of nephrotoxicity noted in the study is far lower than that reported in the 
literature, i.e. 7% vs 25-30%,7-8,22 which may be explained by the uncommon definition of 
nephrotoxicity used in this study. In 2014, Kidera et al published a study of 401 inpatients 
receiving cisplatin as first-line chemotherapy and reported nephrotoxicity in 32% patients, when 
defined as a serum creatinine elevation of 1.5 to 3 times the upper limit of normal.23 On 
multivariable analysis, they observed that non-steroidal anti-inflammatory drug use, 
hypomagnesemia and performance status were significantly associated with nephrotoxicity while 
age, sex and hypoalbuminemia were not. Concurrent chemotherapy and smoking status were not 
evaluated in this study. Neither of the studies evaluated baseline renal function or race, which are 
known risk factors for acute kidney injury.21,23 Liu et al recently described a nephrotoxicity risk 
score that included genetic and non-genetic risk factors based only on 28 cases of nephrotoxicity 
amongst 116 patients, all with lung cancer.24 Furthermore, this study did not include a validation 
cohort to evaluate the performance of their score. Hence, there is need for a larger study of 
patients exposed to cisplatin to be able to build a robust model with a better understanding of risk 
factors and a scoring system that is tested in one or more independent group of patients. 
 
 
INNOVATION: 
Our study is innovative because it ventures to change the paradigm of practice in oncology by re-
evaluating cisplatin candidacy assessment that is based on renal function and risk factors for 
nephrotoxicity. Similar to the widely applicable Framingham risk score,20 we aim to provide 
objectivity to risk assessment in the office using readily available clinical data. The lessons from 
the Framingham risk score application highlight the advantage of having a risk prediction model 
that considers that the presence of moderate-level of multiple risk factors may be more important 
than an isolated presence of one high-level risk factor. 20,25 Presentation of this data in the form 
of a score may also enhance the patient’s understanding of their long-term risk and help them 
make an informed choice regarding their treatment options in consultation with their physician.  
 
We also bring Nephrology expertise to this problem long tackled by Oncologists. We examine 
the use of the more accurate and precise CKD-EPI equation for estimation of GFR for cisplatin 
drug dosing. We will address this problem using data irrespective of cancer type (since 
demographics vary significantly by cancer type) and using a large study population to make the 
results generalizable. We have the opportunity to use data from two large data repositories, the 
Research Patient Data Repository (RPDR) from Partners HealthCare Hospitals and the Oncology 
Data Retrieval System (OncDRS) from the Dana Farber Cancer Institute. We have extensive 
prior experience with retrieving, programming and analyzing the wealth of data from these large 
data sources. 
 
APPROACH: 
 
AIM 1: To compare eligibility with mortality and incidence of cisplatin nephrotoxicity 
when baseline kidney function is estimated by different methods amongst patients who 
have received cisplatin. We hypothesize that an eGFR-based candidate selection by CKD-EPI 
would be superior compared with eGFR by MDRD, estimated creatinine clearance (eCrCl) by 
Cockcroft-Gault and serum creatinine (sCr) at predicting nephrotoxicity and mortality amongst 
those receiving cisplatin. Patients will be divided into categories based on sCr (!1.5mg/dl and 
>1.5mg/dl) eCrCl (≥60 ml/min or <60ml/min) and eGFR (≥60ml/min/1.73 m2 or 
<60ml/min/1.73 m2) by MDRD or CKD-EPI. 
 
1.1: Inclusion and exclusion criteria: 
Our inclusion and exclusion criteria for the two cohorts were as follows: 
Inclusion criteria: 
o! Age "18 years of age 
o! Treated at DFCI main site, BWH or MGH between 2005 and 2015 
o! Patients having at least one baseline serum creatinine measurement within the 
pre-specified period of time (1 month) prior to initial cisplatin exposure and at 
least one creatinine measurement within 14 days after cisplatin exposure. 
Exclusion criteria:  
o! Patients who had cisplatin administered in the setting of allergic desensitization 
 
1.2 Assembly of the cohorts:  
Cohort 1- Massachusetts General Hospital (MGH) data: After receiving Partners Institutional 
Review Board (IRB) approval, we requested the pharmacy research division at the MGH to 
provide a list of patients treated with the drug cisplatin over the past decade. This file included 
patients treated at MGH since the year 2005 reflecting the time that the pharmacy records were 
converted from paper to electronic to enable easier data retrieval. This file contained drug and 
dosing information as well as identifiable patient data including medical record numbers and 
dates of administration. Using the information obtained from pharmacy, we ran a query on the 
Partners RPDR, a data warehouse that collects clinical data from all Partners affiliated hospitals 
that provided us with corresponding data including demographics, medical history, laboratory 
values and medication history.  
 
Cohort 2 - Brigham and Women’s hospital (BWH) and the Dana Farber Cancer Institute (DFCI):  
The majority of the patients in this cohort receive cisplatin as an outpatient at DFCI. This data is 
collected into the OncDRS with pharmacy data incorporated into this repository. We have 
obtained data from the OncDRS system in addition to supplemental data from RPDR. Any 
missing data, erroneous or implausible values were cross-checked between the two databases and 
by chart review to ensure data integrity. 
 
Mortality data: The RPDR and OncDRS systems collect mortality data from respective hospital 
administrative databases as well as the Social Security Death Master Index (SSDMI) that are 
updated monthly. The OncDRS, in addition, also collects death data from the cancer registry and 
National Death Index. 
 
1.3 Definitions: Laboratory data was sorted according to the following definitions: 
Baseline creatinine and additional labs: Labs resulted within 1 month prior to administration of 
the first date of the first course of cisplatin (referred to as index date henceforth) were included 
as the baseline. For patients with multiple lab values, those closest to the index date were chosen 
for inclusion. We also recorded serum magnesium and serum albumin to be included as 
covariates for analysis. The baseline creatinine was chosen from the time closest index date 
because it will likely be the best reflection of renal function at the time of exposure to cisplatin. 
Peak BUN and creatinine: The highest value of creatinine within 14 days following the index 
date was chosen as the peak value. The rationale for choosing this timeline is that most 
nephrotoxicity is seen within 10-14 days of drug administration. Moreover, this is to best 
optimize the number of labs captured despite use of various intervals between cisplatin courses 
for patients included within the cohort (i.e. cisplatin administered every 2, 3 or 4 weeks). 
Nadir creatinine: Labs resulted within 1 month following the index date but occurring after the 
peak value was used to define the nadir. For patients with multiple lab results within this pre-
specified time range, the results reflecting the lowest value of creatinine were chosen. 
Cisplatin-associated nephrotoxicity (CAN):  We define CAN as a "0.3mg/dl rise in creatinine 
from baseline to peak measurements. This definition is adapted from the Acute kidney Injury 
Network (AKIN) criteria 27 which proposes the same degree of rise in creatinine over 48 hours to 
reflect kidney injury. However, based on our prelim data and routine oncology practice, most 
patients do not have a creatinine level re-checked within 48 hours of drug administration. Our 
definition is identical to stage I nephrotoxicity according to the National Cancer Institute’s (NCI) 
nephrotoxicity criteria, which does not specify or restrict the number of hours over which acute 
kidney injury is observed. An additional distinct advantage of using NCI criteria is that they form 
the basis of majority of the literature in cisplatin nephrotoxicity and will help compare our study 
findings with the large body of published data. 
 
Calculation of eGFR by CKD-EPI, MDRD and eCrCl by CG formulae: 
We calculated the eGFR and CrCl as per standard formulae included below using the deemed 
baseline creatinine values and demographics at the time: 
 
CKD-EPI GFR13 = 141 # min (Scr /$, 1)% # max(Scr /$, 1)-1.209 # 0.993Age # 1.018 [if female] 
# 1.159 [if black] 
where: Scr is serum creatinine in mg/dL,$ is 0.7 for females and 0.9 for males, % is -0.329 for 
females and -0.411 for males, min indicates the minimum of Scr /$ or 1, and max indicates the 
maximum of Scr /$ or 1. 
IDMS traceable MDRD eGFR12 (mL/min/1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 x (0.742 
if female) x (1.212 if African American) 
Conventional Units (creatinine as mg/dL; age in years) 
CG: eCrCl 26= [((140-age) x weight)/(72 x Scr)] x 0.85 if female 
Where, eCrCl is expressed in mL/min, age is expressed in years, weight is expressed in 
kilograms, and Scr is expressed in mg/dL 
 
1.4: Statistical analysis: For aim 1, we will analyze the two cohorts combined. Number and 
percentages of patients who would have been eligible to receive the drug by applying four 
different criteria i.e. creatinine !1.5, creatinine clearance "60 ml/min, and eGFR (MDRD) "60 
ml/min/1.73m2 and CKD-EPI "60 ml/min/1.73m2 will be calculated. Event rate of CAN and 
mortality will then be calculated in the entire cohort, and those eligible vs ineligible by each of 
the different criteria i.e, with creatinine !1.5 and creatinine >1.5, creatinine clearance "60 
ml/min and <60ml/min as well as eGFR (MDRD and CKD-EPI) "60 ml/min/1.73m2 and 
<60ml/min/1.73m2. We will then use the paired McNemar tests in order to determine if there are 
statistically significant differences in the number of CAN detected by using the four renal 
function cutoffs mentioned above. All analyses will be carried out using SAS version 9.3. 
 
1.5: Preliminary data:  
During the last year, we requested data from RPDR and OncDRS repositories. This data has 
required extensive processing and programming to be included in the database and to align by 
dates with cisplatin exposure and to ensure data integrity. For cohort 1 (MGH), we received data 
on 2529 patients; after applying the above inclusion and exclusion criteria there were 2254 
eligible patients. Similarly, for cohort 2 (BWH/DFCI), we received data on 5918 patients of 
which 4137 remained eligible. 
 
AIM 2: To develop and validate a clinically useful predictive model for cisplatin 
nephrotoxicity. Our hypothesis is that a model using readily available clinical and laboratory 
variables including the best kidney function measure from Aim (1) will be able to identify 
patients at higher risk for nephrotoxicity amongst candidates for cisplatin chemotherapy and thus 
improve upon current methods of a single cutoff of creatinine or creatinine clearance.  To this 
end, we will: 1) Derive a predictive model using data from patients treated at DFCI and BWH 
(development cohort). We will then test this model in an independent set of patients treated at 
MGH (validation cohort) using Area Under the Curve (AUC) analysis.  
 
2.1: Test/development cohort: We will utilize the larger BWH/DFCI (cohort 2) as described 
above for initial development of the risk score. Important covariates including demographics 
(age, sex, race, height, weight at the time of initial cisplatin administration); history of diabetes, 
hypertension, pre-existing kidney disease (defined as chronic kidney disease with creatinine >1.5 
or eGFR<60ml/min/1.73 m2); cisplatin dose, dose frequency; baseline laboratory values 
including BUN, creatinine, magnesium, albumin; medication history with specific focus on use 
of diuretics, angiotensin converting enzyme inhibitors, amifostine, mannitol; as well as vital 
status will be collected. Missing data will be collected by chart review. CAN will be defined as 
described above in Aim #1. 
 
2.2: Validation cohort:  We will use the MGH (cohort 1) as the validation cohort. All data 
variables as described above for the development cohort will be included and analyzed. 
 
2.3: Statistical analysis: For descriptive purposes, continuous variables will be compared by t-
tests for normally distributed data and Wilcoxon/Kruskal Wallis tests for non-normally 
distributed data as appropriate. Categorical data will be compared using the chi-square test. 
Missing data will be handled by multiple imputation methods after completion of sensitivity 
analysis. We will carry out additional subgroup analysis on patients with creatinine >1.5 or 
eGFR by CKD-EPI <60ml/min/1.73 m2. This will help us evaluate if there are any interactions or 
differing relationships between chronic kidney disease or pre-existing acute kidney injury as 
defined by these frequently used cutoffs and the exposure to cisplatin.  
 
For developing the model using CAN yes/no as the binary primary outcome, we will first 
analyze all the variables with univariable logistic regression. Those that are significant on 
univariate analysis will be entered into a multivariable logistic regression model with backward 
elimination to identify risk factors associated with the primary outcome. Those variables with p-
value <0.05 will be retained in the final model. For each of the significant variables, quintiles of 
& coefficient that are not significantly different from each other will be grouped together. We 
will then divide the & coefficient of these collapsed categories by the smallest value of a & 
coefficient in the model to arrive at a score for every variable. The score will then be 
incorporated into the final model. We will assess the model’s discrimination using the C-statistic 
and calibrate with the Hosmer-Lemeshow goodness-of-fit test using deciles. 95% confidence 
intervals will be calculated using nonparametric bootstrapping. We will proceed with external 
validation using the MGH cohort if the C-statistic is at least 0.70. Sensitivity, specificity, positive 
and negative predictive values will be calculated from both cohorts after selecting an appropriate 
score cutoff to distinguish low risk vs high risk for the primary outcome. In addition, a C statistic 
and H-L p-value will be calculated from the MGH cohort 2. All analyses will be carried out 
using SAS version 9.3. 
 
 
LIMITATIONS AND POTENTIAL SOLUTIONS: 
Serum creatinine continues to present an interesting limitation to any analysis given its limited 
sensitivity and specificity for identification of kidney injury. Despite this, we have chosen to 
identify cisplatin-associated nephrotoxicity using creatinine as our biomarker of choice as is also 
used by the NCI to define nephrotoxicity. Until newer biomarkers are widely adopted, accepted 
and translated into routine clinical practice, we believe this is a clinically relevant choice. This is 
especially the case, given our primary purpose of creating a risk-prediction model out of readily 
available clinical and laboratory variables. Second, we have defined cisplatin-associated 
nephrotoxicity without pathological confirmation. However, a kidney biopsy for tissue-based 
confirmation is rarely performed in this clinical setting, hence this would not be a major change 
from routine clinical practice. Moreover, if significant rise in creatinine is observed within the 
nephrotoxicity time frame, then the clinical practice algorithm (i.e. delaying further 
chemotherapy or discontinuing cisplatin) would likely be no different regardless of the etiology. 
Lastly, this study may also be limited by the fact that the risk prediction model development, 
internal validation and external validation are performed in a tertiary care setting. However, 
these hospitals have a completely separate and independent practice. Our attempts in future years 
would be to further validate the risk score generated from this study in community settings.  
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